NCT06568094View on ClinicalTrials.gov

A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 6, 2024

Primary Completion Date

September 1, 2025

Study Completion Date

December 31, 2026

Conditions
Prostate Cancer
Interventions
DRUG

HRS-5041 tablets

HRS-5041 tablets

DRUG

Abiraterone Acetate tablets（II）

Abiraterone Acetate tablets（II）

DRUG

Prednisone Acetate tablets

Prednisone Acetate tablets

DRUG

Docetaxel Injection

Docetaxel Injection

DRUG

HRS-1167 tablets

HRS-1167 tablets

DRUG

SHR2554 tablets

SHR2554 tablets

Trial Locations (2)

150000

RECRUITING

The Second Affiliated Hospital of Harbin Medical University, Harbin

200433

RECRUITING

Shanghai Jiao Tong University School of Medicine, Renji Hospital, Shanghai

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY